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Tobacco Treatment for Individuals with 
Substance Abuse and Psychiatric 
Disorders 
 
Chizimuzo Okoli, PhD, MPH, RN 
Assistant Professor and Director, 
Tobacco Treatment and Prevention Division, Tobacco Policy Research Program, 
University of Kentucky College of Nursing 
Overview 
 
• Discuss smoking among persons with substance use 
and mental illness 
 
• Present smoking cessation outcomes from an 
evidence-based program for persons with substance 
use disorders and mental Illness 
 
• Conclusion with current and future Projects 
SMOKING AMONG PERSONS WITH  
SUBSTANCE USE AND MENTAL 
ILLNESS 
Background and Significance 
• “Nicotine-dependent 
individuals with a 
comorbid psychiatric 
disorder made up 7.1% 
of the population yet 
consumed 34.2% of all 
cigarettes smoked in the 
United States” 
 
 
 
 
Grant, B.F. , Hasin, D.S., Chou, S.P., Stinson, F.S.& Dawson, D.A. (2004). Nicotine dependence and psychiatric disorders in the United States: Results from a 
national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry,61,1107-1115. 
Past Month Cigarette Use among Adults Aged 18 or Older, by Any Mental Illness in 
the Past Year and Gender, by Age Group: 2009 to 2011 
 Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123  
Health effects of smoking among 
persons with mental illness 
Nonsmokers with Mental illness : 
• Have better health 
• Live longer 
• Need less medication 
• Have less depression 
• Save more money 
 
 
 
 
Smokers with Mental illness : 
• Die 10 years earlier 
• Have more depression and 
anxiety 
• Have more substance use 
problems 
• Have more chest and heart 
problems 
• Are more likely to commit 
suicide 
• Have sexual problems 
 
 
 
 
Reasons for smoking among individuals with 
substance use disorders and mental illness 
 
 
• Psychosocial 
• Genetic • Bio-behavioral 
Smoking and substance use: Genetic 
• Both common and specific addictive factors for alcohol, marijuana, 
cocaine, and habitual smoking transmitted in families 
 
• This specificity suggested independent causative factors for the 
development of each substance dependence 
 
• 68% of the association between nicotine and alcohol dependence 
explained by shared genetic effects. 
 
Bierut LJ, Dinwiddie SH, Begleiter H, et al. Familial Transmission of Substance Dependence: Alcohol, Marijuana, Cocaine, and Habitual Smoking: A Report From the Collaborative 
Study on the Genetics of Alcoholism. Archives of General Psychiatry 1998; 55:982-988 
True WR, Xian H, Scherrer JF, et al. Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men. Archives of General Psychiatry 1999; 56:655-661 
Smoking and mental illness: Genetic 
 
(8,169 male twins) shared 
genetic factors further explain 
the relationship between 
major depression and nicotine 
dependence.  
 
Kendler KS, Neale MC, MacLean CJ, et al. Smoking and Major Depression: A Causal Analysis. Archives of General Psychiatry 1993; 50:36-43 
Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine & Tobacco Research 
2008; 10:97 - 108 
(1,566 female twin pairs) average life 
time daily cigarette consumption was 
found to be associated with life time 
prevalence of major depression, 
suggesting that the relationship 
between smoking and major 
depression resulted solely from genes 
which predispose to both conditions. 
• 63% of the association between post traumatic stress disorder 
and nicotine dependence co-morbidity explained by shared 
genetic effects. 
Koenen KC, Hitsman B, Lyons MJ, et al. A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine Dependence in Men. Archives of 
General Psychiatry 2005; 62:1258-1265 
Faraone et al. (2004). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in Schizophrenia families 
Smoking and mental illness: Genetic   
• A group of candidate genes and individual genes found 
among individuals with schizophrenia significantly linked to 
smoking behaviors. 
Smoking and substance use: Bio-behavioral 
Marijuana use reduces cessation of tobacco smoking 
in adults 
Ford, Vu, Anthony. (2002) Drug and Alcohol Dependence; 67:243-248 
 
 
 
Nicotine increases alcohol self-administration in 
non-dependent male smokers.  
Barrett,Tichauer, Leyton, et al. (2006). Drug and Alcohol Dependence; 81:197-204 
 
 
 
 
Increases in methadone dose could increase nicotine 
craving and cigarette consumption for individuals 
with opioid-dependence  
Story & Stark. (1991). Journal of psychoactive drugs, 23:203-215 
 
 
Cigarette smoking primes the brain to cocaine use 
Levine et al. (2011). Science translational medicine, 3, 107, 107-109  
 
 
 
 
 
 
 
Smoking and mental illness: Bio-behavioral 
 
 
 
 
 
 
Nicotine reduces sensorimotor gating deficits in 
smokers with schizophrenia 
Postma et al. (2006). Psychopharmacology, 184: 589–599 
 
 
 
 
 
Brain levels of monoamine oxidase A (MAO-A) (an 
enzyme associated with depression) were reduced 
in smokers relative to nonsmokers; suggesting that 
people with affective disorders may smoke to 
reduce elevated MAO-A levels in the brain 
Fowler, Volkow, Wang, et al. (1996). Proceedings of the National Academy of Sciences of the United States of America, 93:14065-14069 
 
Smokers with a primary diagnosis of anxiety 
disorder reported greater levels of general anxiety, 
distress, and depression as compared to 
nonsmokers. 
McCabe, Chudzik, Antony, et al. (2004). Journal of Anxiety Disorders, 18:7-18 
Substance use and Smoking: Psychosocial 
Glautier S, Clements K, White JAW, et al. Alcohol and the reward value of cigarette smoking. Behavioural Pharmacology 1996; 7:144-154 
King AC, Epstein AM. Alcohol Dose-Dependent Increases in Smoking Urge in Light Smokers. Alcoholism: Clinical & Experimental Research 2005; 29:547-552 
Friend KB, Pagano ME. Smoking initiation among nonsmokers during and following treatment for alcohol u se disorders. Journal of Substance Abuse Treatment 2004; 26:219-224 
Bobo JK, Husten C. Sociocultural Influences on Smoking and Drinking. Alcohol Research & Health 2000; 24:225-232 
Crum RM, Lillie-Blanton M, Anthony JC. Neighborhood environment and opportunity to use cocaine and other drugs in late childhood and early adolescence. Drug and Alcohol 
Dependence 1996; 43:155-161 
Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am. J. Epidemiol. 
2002; 155:918-925 
• Tobacco use may foster the use of other substances; and 
vice versa 
• Drug treatment centers may provide an environment 
that supports tobacco use or a factor for delayed 
tobacco use cessation. 
• Factors such as neighborhood disadvantage and early 
exposure to substance use may present an ‘exposure 
opportunity’ for subsequent substance use.  
Smoking mental illness: Psychosocial 
• History of tobacco use as a token economy--
cigarettes used as a ‘reward’ for appropriate 
behavior (i.e., smoking privileges) 
 
 
 
 
• Smoking among clients and staff to encourage 
‘socialization’  
 
Kawachi I, Berkman L. Social ties and mental health. Journal of Urban Health 2001; 78:458-467 
Lawn S. Cigarette smoking in psychiatric settings: occupational health, safety, welfare and legal concerns. Australian and New Zealand Journal of Psychiatry 2005; 39:886-891 
Keizer I, Eytan A. Variations in Smoking during Hospitalization in Psychiatric In-Patient Units and Smoking Prevalence in Patients and Health-Care Staff. International Journal of Social 
Psychiatry 2005; 51:317-328 
Morisano D, Bacher I, Audrain-McGovern J, et al. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Canadian Journal Of Psychiatry. Revue 
Canadienne De Psychiatrie 2009; 54:356-367 
Arguments for Not Providing Tobacco Treatment…. 
“these patients don’t want to quit” 
• However….80% of participants in a methadone maintenance 
program and 75% of participants in an alcohol abuse 
program endorsed a desire to quit  
(Richter KP et al., 2001; Ellingstad TP et al, 1999)  
 
 
 
• In a review of 9 studies of motivation to quit smoking among 
individuals with psychiatric disorders at least 50% are 
contemplating cessation  
(Siru, Hulse & Tait, 2009).  
“these patients will relapse (to other substances) if 
they try to quit” 
 
• Smoking cessation related to IMPROVED QUALITY OF LIFE 
 
 
 
 
 
• Meta-analysis (n = 19 studies) of smoking cessation among 
individuals in addiction treatment and recovery found that 
smoking cessation efforts can ENHANCE rather than 
compromise long-term sobriety  
 
 
 
 
 
 
 
 
 
 
Bobo JK, McIlvain HE, Lando HA, et al. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 1998; 93:877-
887 
McCarthy WJ, Zhou Y, Hser YI, et al. To smoke or not to smoke: Impact on disability, quality of life, and illicit drug use in baseline polydrug users. Journal of Addictive Diseases 2002; 21:35-54 
Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome. Addictive Behaviors 2003; 28:1323-1331 
Mc Carthy WJ, Collins C, Hser YI. Does cigarette smoking affect drug abuse treatment? Journal of Drug Issues 2002; 2:61-80 
Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical 
Psychology 2004; 72:1144-1156 
“these patients are unable to quit” 
• Meta-analysis (n = 19 studies) of smoking cessation among 
individuals in addiction treatment and recovery found increased 
cessation at end of 12 weeks treatment 
     (Prochaska JJ et al, 2004). 
 
 
• Another recent study found end-of-treatment (between 8 to 26 
weeks) smoking cessation rates of 40% among individuals with 
SUD and/or PD who completed an intensive tailored smoking 
cessation intervention that provided no-cost pharmacotherapy 
combined with behavioural counseling 
         (Khara and Okoli, 2011) 
           
 
• Concerns that smoking cessation will increase 
psychiatric symptoms or relapse among patients.  
o Among individuals with depression, smoking cessation related to 
increased depression symptomatology, which is one of the 
symptoms of the nicotine withdrawal syndrome 
o individuals with anxiety disorders and depression report more 
severe withdrawal symptoms 
o smoking is associated with improvements in prepulse inhibition 
and sensory gating which may be affected by smoking cessation 
 
• Smoke-free policy and mental health facilities 
o a review of studies examining prohibitions of smoking in 
psychiatric facilities suggests that prohibitions do not have long-
term effects on behavioral unrest or noncompliance, but neither 
do they appear to effect smoking cessation 
Patten C, Martin J. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine 1996; 18:190-200 
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry 1992; 
149:464-469 
Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience 2007; 12:4755-4772 
Kumari V, Postma P. Nicotine use in schizophrenia: The self medication hypotheses. Neuroscience & Biobehavioral Reviews 2005; 29:1021-1034 
el-Guebaly N, Cathcart J, Currie S, et al. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatr Serv 2002; 53:1617-1622 
Ziedonis DMa, Williams JMb. Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry 2003; 16:305-315 
Barriers to facilitating tobacco treatment 
Costs associated with smoking cessation treatment 
• Even though less expensive than purchasing cigarettes, 
the cost of pharmacotherapy and counseling presents 
an important barrier to seeking treatment 
 
• Such cost barriers to accessing treatment and the 
potential cost-effectiveness of treatment have 
prompted guidelines about reducing medication costs 
(reduced cost or free of charge), inclusion of 
medications as benefits on drug insurance plans, and 
setting up systems for reimbursement for tobacco 
cessation treatment for health care providers. 
Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research 2004; 6:303-
310 
Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing 2006; 15:272-278 
Fiore M, Jaén C, Baker T, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive 
Medicine 2008; 35:158-176 
Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. British Medical Journal 1999; 318:182-185 
Smoking Cessation Outcomes of an evidence-
based program for individuals with Substance 
Use Disorders and Mental Illness 
          
Program Overview 
• 24-26 weeks (8 weeks structured, up to 18 weeks of support) 
 
• Tailored pharmacotherapy for up to 26 weeks at no 
cost 
 
• Program is run with a team of nurses, counsellors, 
respiratory therapists, Occupational therapists, and 
a physician 
 
 
TREATMENT PHILOSOPHY 
Smoking cessation is a ‘process’ not an event. Hence the program has no 
specific ‘quit date’. Also the program employs the concept of ‘titration-to-
effect’ in which increasing doses of nicotine replacement therapy is 
provided until the behavior of smoking ceases.   
Criteria 
Eligibility: 
• 19 years or older 
• Tobacco dependent 
• Have a history of substance use disorder (SUD) and/or 
psychiatric disorder (PD) 
• Financially disadvantaged 
 
Assessment: 
• 1 hour evaluation of medical, psychiatric, substance 
and tobacco use history 
• Expired air CO is determined and a treatment plan is 
developed in consultation with client 
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Behavioral Counseling  
 
Support Group 
Tailored 
 Pharmacotherapy 
Behavioural Counseling (Weeks 1-8) 
• Phase 1: engagement in the process – weeks 1-2 
 
• Phase 2: planning for change – weeks 3-4 
 
• Phase 3: sustaining change – weeks 5-8 
Combination Pharmacotherapy 
Nicotine Replacement Therapy 
 
 
 
Oral Medications  
 
 
 
Patch 
Gum 
Lozenge 
Inhaler 
Zyban 
Champix 
  
  
Screen clipping taken: 12/03/2011, 11:18 AM 
  
  
Pacific Spirit 
Three Bridges 
Rainier 
Pender Clinic DCHC 
Raven Song 
Centre for Concurrent  Disorders 
Sample for Evaluation 
678 
Intent-to-treat 
155 
Program non-completers 
523 
program completers 
• Analysis is based on a retrospective chart review of participants in the TDC 
program (between Sept 2007 and Dec, 2011) from 7 clinics, in Vancouver, Canada 
 
• Smoking cessation: 7-day point-prevalence of abstinence at end of treatment  
(i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels 
Substance Use Disorder & Psychiatric Disorder History 
 (N = 678) 
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Sample Characteristics (N = 678, 57% male) 
Mean Stand. Dev. 
Age of participant (years) 
 
48.0 11.0 
Age at smoking initiation (years) 
 
15.1 5.8 
Importance of quitting (scale of 0 ‘low’ to 10 ‘high’) 9.0 1.4 
Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’) 
 
7.2 2.4 
Number of cigarettes smoked per day 
 
20.4 10.3 
Fagerstrom Test for Nicotine Dependence  
(scale of 0 ‘low’ to 10 ‘high’) 
 
6.0 2.0 
CO level at baseline (ppm) 20.9 14.2 
Program Completion (n = 523/678) 
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Smoking Cessation* Outcomes at end-of-treatment  
*Smoking cessation at end-of-treatment (i.e., anytime between 8 weeks to 26 weeks) 
verified by expired CO levels 
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Quit
Not quit
Smoking cessation by SUD and PD among 
program completers (n = 523)* 
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* No statistically significant differences between groups 
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* No statistically significant differences between groups 
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Multivariate predictorsa of program completion (n = 674) 
a. Employing a two-step model building process in which variables associated with 
smoking cessation (at alpha < 1.0) in the unadjusted analyses are included in a 
second-step for adjusted analyses. Only variables which were significantly predictive of 
smoking cessation in the final adjusted multivariate model are shown.  
 
* = p <.05, ** = p <.001, *** = p <.001 
Predictors Odds Ratio 95%CI 
Gender 
Male (referent) 
Female 
 
     1.0 
1.78** 
 
- 
1.19-2.65 
       Age 1.03** 1.01-1.05 
Hosmer-Lemeshow goodness-of-fit: χ2= 1.80 (DF=8),  p=.986 
Multivariate predictorsa of smoking cessation among 
program completers at end of treatment (n = 494) 
a. Employing a two-step model building process in which variables associated with smoking cessation (at alpha < 1.0) 
in the unadjusted analyses are included in a second-step for adjusted analyses. Only variables which were 
significantly predictive of smoking cessation in the final adjusted multivariate model are shown.  
 
* = p <.05, ** = p <.001, *** = p <.001 
Predictors Odds Ratio 95%CI 
History of Psychiatric Disorder 
None (referent) 
Mood disorder 
Anxiety disorder 
Psychotic disorder 
 
1.0 
.90 
.53* 
.69 
 
- 
.57-1.42 
.29-1.00 
.31-1.57 
FTND at baseline .89* .80-1.00 
       Number of Visits to the TDC 1.07*** 1.04-1.10 
Hosmer-Lemeshow goodness-of-fit: χ2= 3.45 (DF=8),  p=.903 
Conclusions 
 
• With intensive tobacco dependence treatment provided 
within Mental Health and Addictions services, individuals 
with a history of substance use disorders and mental illness 
are able to achieve smoking abstinence. 
 
• Tobacco treatment should include best practices using 
behavioural counseling combined with pharmacotherapy.  
 
• Treatment durations beyond 12-weeks should be 
considered to maximize effectiveness of programs 
 
 
 
Current and Future Projects 
• Current projects: 
o Smoking Cessation Program among Individuals with Mental 
Illness (PARTICIPATION STATION- a peer led mental health 
support program in Lexington KY) 
o Developing a tailored tobacco dependence treatment 
intervention for individuals with Schizophrenia 
 
 
• Future Projects: 
o Examining the effect of different tobacco products on nicotine 
dependence, symptoms severity, and smoking cessation 
among individuals with mental illnesses. 
o Examining barriers and opportunities to engagement and 
provision of tobacco treatment within mental health treatment 
facilities 
Questions?? 
 
